Combinations of CDK4/6 inhibitors with AIs or SERDs/SERMs (selective ER down regulators/selective ER modulators) significantly improved progression free-survival of patients with ER-positive metastatic BC [32,33,34]. Here, CDK4 is linked to breast cancer.